No Data
No Data
FDA Lifts Clinical Hold on CytoDyn Drug, Stock Rallies 22%
Express News | CytoDyn Announces Submission Of Clinical Protocol To FDA And Initiation Of Pre-Clinical Study In Glioblastoma
Express News | CytoDyn Appoints Jacob Lalezari As CEO, Effective Jan. 26, 2024; Mitchell Cohen Appointed Interim CFO, Effective Feb. 1, 2024
CytoDyn Appoints Lalezari as Its Interim CEO
CytoDyn President Cyrus Arman Takes Medical Leave
CytoDyn to Host Conference Call
No Data